Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779582 | 0.89 | CHRM2 (0.68) | CHRM2KDM4EPOLBSCN8AMEN1 | |
| SCHEMBL22839742 | 0.89 | CHRM2 (0.92) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL2930997 | 0.89 | CHRM2 (0.85) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL7981763 | 0.88 | CHRM2 (0.84) | CHRM2KDM4EPOLBSCN8AMEN1 | |
| Hydrochloric Acid SCHEMBL27669851 | 0.87 | CHRM2 (0.66) | CHRM2KDM4EPOLBSCN8AMEN1 | |
| SCHEMBL2938432 | 0.85 | CHRM2 (0.78) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL10382814 | 0.84 | CHRM2 (0.77) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL4919379 | 0.83 | CHRM2 (0.81) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL5040557 | 0.83 | CHRM2 (0.81) | CHRM2KDM4ESCN8AMEN1KMT2A | |
| SCHEMBL4914700 | 0.83 | CHRM2 (0.81) | CHRM2KDM4ESCN8AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116648248-B | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116648248-A | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4225749-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022161414-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATION THEREOF | 成都茵创园医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2414349-A1 | 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-7335659-B2 | Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | N.V. ORGANON (NL) | 2008-02-26 | — | — | US | disclosed |
| US-7335659-B2 | Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | N.V. ORGANON (NL) | 2008-02-26 | — | — | US | disclosed |
| EP-0517877-A1 | NOVEL 3(2H)-PYRIDAZINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992012137-A1 | NOVEL 3(2H)-PYRIDAZINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CHRM2 4734/4885KDM4E 2150/4885POLB 1606/4885 |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | CHRM2 732/4885KDM4E 2054/4885POLB 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.